Key Investor Signals
Approximately €3M raised from biotech investors
Biotech venture builder BaseLaunch joined High-Tech Gründerfonds, LBBW Venture Capital and L-Bank-backed InnoGrowth BW in February 2026, bringing total pre-seed financing to approximately €3 million.
Cell paper validates founding RNA target biology
Co-founder Bastian Linder led the 2025 Cell study showing that a tRNA modification stabilizes cancer-related mRNA, providing peer-reviewed validation of Umlaut.bio's founding target biology.
Development lead brings ~€250M biotech exit experience
CDO Simon Breitler co-founded eracal therapeutics and served as COO before its acquisition by Novo Nordisk for approximately €250 million in upfront and milestone payments, plus royalties.
Other Positive Signals
- Selected for pharma-backed programmes involving Eli Lilly, Ono Pharmaceutical and AbbVie.
- Systemic sclerosis specialist Oliver Distler and tRNA researcher Tsutomu Suzuki joined the Scientific Advisory Board in 2026.
- EMBL's technology-transfer arm provided early funding to translate the founding research towards therapeutic development.
Team
Karsten Fischer
Co-founder and CEO
- Led Memo Therapeutics as CEO from 2018 to 2024 through pivotal Phase II/III development and a partnership with Ono Pharmaceutical.
- Previously served as a partner at BioMedPartners after more than ten years across biotechnology investment banking and venture capital.
- Managed more than $500M in financing events across roles as an investment banker, investor and biotechnology CEO.
Bastian Linder
Co-founder and CSO
- First-authored the 2025 Cell paper defining the tRNA–mRNA mechanism underlying Umlaut.bio's therapeutic approach.
- At Weill Cornell Medicine, developed a method to map m6A RNA modifications at single-nucleotide resolution across the transcriptome.
- Conducted the foundational tRNA research in Lars Steinmetz's group at the European Molecular Biology Laboratory.
Product
Umlaut.bio is developing small-molecule inhibitors of enzymes that add disease-associated chemical marks to transfer RNA. Its discovery platform is designed to find active compounds, confirm that they reduce the intended modification and support multiple programmes across cancer and inflammatory disease.
Disease-linked RNA control
The company targets enzymes that modify transfer RNA. Its founding research showed that these modifications can determine whether some messenger RNA molecules are degraded or remain available to drive protein production.
Small-molecule enzyme inhibitors
Umlaut.bio is designing compounds to block selected tRNA-modifying enzymes. The approach uses conventional small molecules to intervene in RNA regulation rather than delivering RNA as the therapy.
Screening with target confirmation
The platform screens compounds at high throughput and uses mass spectrometry to confirm that the intended RNA modification has been reduced, linking compound activity directly to target inhibition.
Market Overview
Umlaut.bio is building a discovery platform for oncology and inflammatory disease rather than a single disclosed asset. Its small-molecule strategy addresses two established therapeutic markets while creating the possibility of multiple programmes against distinct tRNA-modifying enzymes.
Systemic sclerosis gives Umlaut.bio a defined autoimmune indication alongside its oncology programmes. The rare disease can damage the skin, blood vessels and internal organs, and gives the company a focused initial disease area within a broader platform designed to generate multiple programmes.
Market value across cancer medicines, according to Fortune Business Insights.
Global market value for treatments targeting autoimmune diseases.
Estimated number of people living with systemic sclerosis worldwide.
Estimated global market value for systemic sclerosis treatments.
Comparable Outcomes
Flexus Biosciences
Flexus developed small molecules designed to reverse tumor immune suppression. Its lead asset, F001287, had not entered clinical trials when the company was sold. Bristol-Myers Squibb acquired Flexus in 2015 for $800 million upfront and up to $450 million in development milestones, bringing the potential value to $1.25 billion.
Peloton Therapeutics
Peloton developed oral small molecules targeting HIF-2α, a tumor pathway linked to kidney cancer. Its lead candidate, PT2977, had reached late-stage development when the company was sold. Merck acquired Peloton in 2019 for $1.05 billion upfront and up to $1.15 billion in milestones, taking the potential value to $2.2 billion.
Interested in More Startups Like Umlaut.bio?
Get a curated pipeline of healthcare and life sciences startups aligned with your investment thesis.
Sources
This profile was built from public company materials, ecosystem sources, market references, and professional profiles.